D-index dose not predict the development of pulmonary infection in acute myeloid leukemia patients undergoing consolidation chemotherapy with high-dose cytarabine

被引:15
|
作者
Kimura, Shun-ichi [1 ]
Wada, Hidenori [1 ]
Ishihara, Yuko [1 ]
Kawamura, Koji [1 ]
Sakamoto, Kana [1 ]
Yamasaki, Ryoko [1 ]
Ashizawa, Masahiro [1 ]
Machishima, Tomohito [1 ]
Sato, Miki [1 ]
Terasako, Kiriko [1 ]
Nakasone, Hideki [1 ]
Kikuchi, Misato [1 ]
Okuda, Shinya [1 ]
Kako, Shinichi [1 ]
Kanda, Junya [1 ]
Yamazaki, Rie [1 ]
Tanihara, Aki [1 ]
Nishida, Junji [1 ]
Kanda, Yoshinobu [1 ]
机构
[1] Jichi Med Univ, Saitama Med Ctr, Div Hematol, Saitama 3308503, Japan
关键词
Neutropenia; D-index; Pulmonary infection; Acute myeloid leukemia; High-dose cytarabine; INVASIVE FUNGAL DISEASE; NEUTROPENIC PATIENTS; HIGH-RISK; CURVE; AREA;
D O I
10.1179/1607845413Y.0000000103
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The D-index is calculated as the area over the neutrophil curve during neutropenia. We investigated the impact of the D-index on pulmonary infection in 33 acute myeloid leukemia patients undergoing consolidation chemotherapy with high-dose cytarabine. There was no difference in the D-index between chemotherapies with and without pulmonary infection. The cumulative D-index (c-D-index) until the development of infection exceeded 4000 in four of five patients with pulmonary infection. Although there was no difference in the total D-index throughout the overall consolidation chemotherapy, the total D-index from induction to consolidation and the D-index at induction chemotherapy were higher in patients with pulmonary infection during consolidation than in those without it (P = 0.014 and 0.019, respectively). Our results showed that the cumulative effect of neutropenia might determine the risk of pulmonary infection in consolidation chemotherapy. We are planning a clinical trial of c-D-index-guided preemptive antifungal therapy.
引用
收藏
页码:107 / 112
页数:6
相关论文
共 50 条
  • [31] High-Dose Cytarabine Alone Versus Cytarabine Plus Anthracycline for Consolidation Therapy in Non-Promyelocytic Acute Myeloid Leukemia
    Kim, Sung-Hyun
    Kim, So Yeon
    Lee, Ji Hyun
    Lee, Suee
    Oh, Sung Yong
    Kim, Hyo-Jin
    Kim, Dae Sik
    Kang, Ka-Won
    Lee, Se Ryeon
    Park, Yong
    Sung, Hwa Jung
    Choi, Chul Won
    Kim, Byung Soo
    BLOOD, 2015, 126 (23)
  • [32] HIGH-DOSE CYTARABINE IN ACUTE MYELOGENOUS LEUKEMIA
    ZITTOUN, R
    BONE MARROW TRANSPLANTATION, 1989, 4 : 38 - 42
  • [33] Neutropenia in the First Cycle of Consolidation Chemotherapy with High-Dose Cytarabine Is Not Associated with the Incidence of Relapse in Adult Acute Myeloid Leukemia Patients in First Complete Remission
    Kimura, Shun-Ichi
    Nakamura, Yuhei
    Kawamura, Masakatsu
    Takeshita, Junko
    Kawamura, Shunto
    Yoshino, Nozomu
    Misaki, Yukiko
    Yoshimura, Kazuki
    Matsumi, Shimpei
    Gomyo, Ayumi
    Okada, Yosuke
    Akahoshi, Yu
    Tamaki, Masaharu
    Kusuda, Machiko
    Kameda, Kazuaki
    Wada, Hidenori
    Sato, Miki
    Tanihara, Aki
    Nakasone, Hideki
    Kako, Shinichi
    Kanda, Yoshinobu
    ACTA HAEMATOLOGICA, 2022, 145 (04) : 404 - 411
  • [34] Intensive timed sequential remission induction chemotherapy with high-dose cytarabine for childhood acute myeloid leukemia
    Loeb, DM
    Bowers, DC
    Civin, CI
    Friedman, AD
    MEDICAL AND PEDIATRIC ONCOLOGY, 2001, 37 (04): : 365 - 371
  • [35] High-dose cytarabine, etoposide and cisplatin salvage chemotherapy for relapsed adult acute myeloid leukemia.
    Lee, JS
    Lee, KW
    Lee, WS
    Kim, J
    Yoon, SS
    Park, S
    Kim, BK
    BLOOD, 2003, 102 (11) : 230B - 230B
  • [36] Impact of pegylated filgrastim in comparison to filgrastim for patients with acute myeloid leukaemia (AML) on high-dose cytarabine (HIDAC) consolidation chemotherapy
    Grace Kam
    Richard Yiu
    Yvonne Loh
    Ai Leen Ang
    Ling Ling Yueh
    Yeow Tee Goh
    Gee Chuan Wong
    Supportive Care in Cancer, 2015, 23 : 643 - 649
  • [37] Safety, Feasibility, and Cost-Effectiveness with Outpatient Administration of High-Dose Cytarabine Consolidation in Acute Myeloid Leukemia
    Wetzstein, Gene A.
    Lancet, Jeffrey E.
    Kallner, Jennifer E.
    Sivik, Jeffrey M.
    Ho, Viet Q.
    George, Timothy J.
    Desai, Sheetal
    Fisher, Shanel
    Newton, Michael D.
    List, Alan F.
    BLOOD, 2008, 112 (11) : 838 - 839
  • [38] Impact of pegylated filgrastim in comparison to filgrastim for patients with acute myeloid leukaemia (AML) on high-dose cytarabine (HIDAC) consolidation chemotherapy
    Kam, Grace
    Yiu, Richard
    Loh, Yvonne
    Ang, Ai Leen
    Yueh, Ling Ling
    Goh, Yeow Tee
    Wong, Gee Chuan
    SUPPORTIVE CARE IN CANCER, 2015, 23 (03) : 643 - 649
  • [39] Takotsubo Cardiomyopathy after Systemic Consolidation Therapy with High-Dose Intravenous Cytarabine in a Patient with Acute Myeloid Leukemia
    Baumann, Stefan
    Huseynov, Aydin
    Goranova, Diana
    Faust, Melanie
    Behnes, Michael
    Nolte, Florian
    Heidenreich, Daniela
    Hofmann, Wolf-Karsten
    Borggrefe, Martin
    Akin, Ibrahim
    Klein, Stefan
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 (09) : 487 - 490
  • [40] Efficacy of delayed pegfilgrastim administration following consolidation therapy with high-dose cytarabine (HiDAC) in acute myeloid leukemia (AML) patients
    Yingling, Spencer K.
    Francis, Joshua
    Seago, Kelsea
    Safi, Salah Ud Din
    Wen, Sijin
    Cumpston, Aaron
    SUPPORTIVE CARE IN CANCER, 2024, 32 (05)